Very happy w/ PR today and this is what I have concluded as to what I believe (or hope) is happening:
Kevetrin Phase 1 ended on 16 Feb 2016. Phase 2 Ovarian Trial didn't start until the beginning of 2017 and this trial IMO was designed with a great deal of input by those scientific minds from the BP. It wanted to see p53 activated and it wanted to see safety as the P2 included dosing 3 times per week whereas P1 only had dosing 1 time per week.
The major question to me is what came out of the mtg with the BP CEO and major scientists around early 2017 as mentioned in the PR today? No immediate deal seems to have been made as to BP stepping up to cover the costs of the P2 Ovarian trial, but could something bigger and further down the line have been developed?
Nobody can say for sure, but IMO the CEO of the BP should be fired if he didn't make sure IPIX knew he would step up to the plate in a BIG BIG way once IPIX showed definite p53 efficacy in the trial and that they could formulate it into a pill should the data indicate the drug continued to clear out of the system so quickly.
The P2 trial showed in no uncertain terms that the efficacy of Kevetrin was beyond doubt and per a company PR (or filing, not sure) in the Spring of 2017 IPIX expected the oral formulation to be completed and ready for testing on healthy patients around the end of 2017/beginning of 2018. That was put on hold due to financial reasons, but could the BP have been aiding IPIX in developing the oral formulation? We certainly didn't have the funds to work on it over the last year, but here we find out it is done and ready for the choosing of a CRO to do the bridging toxicology work. Mighty impressive advancement for a seemingly dead project until new monies were available.
Could an understanding have been developed between IPIX/BP as to funding of oral formulation, toxicology testing, and P3 testing regarding Kevetrin without having to be PR'd? I don't know if this could legally be done or not. Maybe it is just an understanding at this point in time where BP gets right of last refusal for K platform if they help out on costs up to or thru P3. All I know is if I was the CEO and I saw the p53 possibilities of Kevetrin that I wouldn't have let IPIX leave the table until they agreed that I would have first and last shot at the Kevetrin platform.
Leo has been surprising everyone since last spring w/ the Evonik and CoreRx signings and this pill testing is another major event in that line. I laugh thinking of the clowns on the multi-face board trying to convince people Leo laying on the beach in FL all day doing nothing.
Next 3 weeks sure look like they are going to hold some major fireworks for us longs.
Kevetrin Phase 1 ended on 16 Feb 2016. Phase 2 Ovarian Trial didn't start until the beginning of 2017 and this trial IMO was designed with a great deal of input by those scientific minds from the BP. It wanted to see p53 activated and it wanted to see safety as the P2 included dosing 3 times per week whereas P1 only had dosing 1 time per week.
The major question to me is what came out of the mtg with the BP CEO and major scientists around early 2017 as mentioned in the PR today? No immediate deal seems to have been made as to BP stepping up to cover the costs of the P2 Ovarian trial, but could something bigger and further down the line have been developed?
Nobody can say for sure, but IMO the CEO of the BP should be fired if he didn't make sure IPIX knew he would step up to the plate in a BIG BIG way once IPIX showed definite p53 efficacy in the trial and that they could formulate it into a pill should the data indicate the drug continued to clear out of the system so quickly.
The P2 trial showed in no uncertain terms that the efficacy of Kevetrin was beyond doubt and per a company PR (or filing, not sure) in the Spring of 2017 IPIX expected the oral formulation to be completed and ready for testing on healthy patients around the end of 2017/beginning of 2018. That was put on hold due to financial reasons, but could the BP have been aiding IPIX in developing the oral formulation? We certainly didn't have the funds to work on it over the last year, but here we find out it is done and ready for the choosing of a CRO to do the bridging toxicology work. Mighty impressive advancement for a seemingly dead project until new monies were available.
Could an understanding have been developed between IPIX/BP as to funding of oral formulation, toxicology testing, and P3 testing regarding Kevetrin without having to be PR'd? I don't know if this could legally be done or not. Maybe it is just an understanding at this point in time where BP gets right of last refusal for K platform if they help out on costs up to or thru P3. All I know is if I was the CEO and I saw the p53 possibilities of Kevetrin that I wouldn't have let IPIX leave the table until they agreed that I would have first and last shot at the Kevetrin platform.
Leo has been surprising everyone since last spring w/ the Evonik and CoreRx signings and this pill testing is another major event in that line. I laugh thinking of the clowns on the multi-face board trying to convince people Leo laying on the beach in FL all day doing nothing.
Next 3 weeks sure look like they are going to hold some major fireworks for us longs.
11
